Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly


Abstract
Subcutaneous octreotide (Sandostatin) injections lead to gall stone formation in 13–50% of acromegaly patients during one year of therapy. This study explored the effects of octreotide on interdigestive gall bladder emptying, antroduodenal motility, and motilin release. Ambulatory antroduodenal manometry was performed in six acromegaly patients before and after two months of octreotide therapy (100 µg thrice daily, subcutaneously). Ultrasonographic gall bladder volume measurements and plasma motilin concentrations were obtained during two migrating motor complex (MMC) cycles. Before octreotide treatment, nine of 26 phase III activities started in the antrum and 17 of 26 in the duodenum whereas during treatment 47 of 48 of phase III activity started in the duodenum (p<0.05). Before treatment, interdigestive gall bladder emptying (mean (SEM) 39.9 (4.0)% of maximal fasting volume) and plasma motilin peaks preceded antral phase III but not duodenal phase III. During octreotide therapy no significant motilin fluctuation or gall bladder emptying was seen. Fasting gall bladder volume increased from 40.9 (9.1) ml before to 68.0 (14.8) ml (p<0.05) during octreotide treatment. In conclusion, two months’ treatment with octreotide increases the number of duodenal phase III like activity and virtually abolishes antral phase III, plasma motilin peaks, and interdigestive gall bladder emptying. These effects might contribute to the high risk of gall stone formation during longterm octreotide treatment.

Keywords: gall bladder motility, gall stone formation, interdigestive manometry, migrating motor complex, octreotide.

Methods

Subjects
Six patients with active acromegaly, requiring octreotide therapy, were enrolled in the study.

Subcutaneous injections with the somatostatin analogue octreotide (SMS201-995, Sandostatin) are an effective treatment for acromegaly, but lead to gall stone formation in 13–50% of cases during one year of therapy.1 The mechanism by which octreotide induces gall stones is not completely clear. Octreotide suppresses postprandial gall bladder contraction for several hours.2 3 In addition, fasting gall bladder volume is increased during octreotide treatment, which may show that interdigestive gall bladder emptying is also disturbed.2 3 Several studies have shown that interdigestive gall bladder emptying is related to the migrating motor complex (MMC).4-7 The MMC is a characteristic cyclic triphasic pattern of motor activity of the gastrointestinal tract. Phase III (strong contractions with maximal frequency) is probably responsible for the ‘housekeeping’ function of the MMC – that is, aboral propulsion of indigestible debris and prevention of small intestinal bacterial overgrowth.8 Phase III may originate in the antrum or in the duodenum. The start of phase III in the antrum is preceded by significant gall bladder emptying and motilin release whereas origination of phase III in the duodenum is not associated with these events.9 10 It is well known that somatostatin and octreotide have strong effects on the MMC in short term experiments.11-15 Single octreotide injections exclusively induce duodenal phase III like activity and suppress antral phase III. Moreover, motilin release is suppressed.13 14 However, the effects of longterm octreotide therapy on gastrointestinal motility are unknown. We hypothesised that in the fasting state, longterm octreotide administration is associated with an excess of duodenal phases III and gall bladder hypomotility. This study therefore examined the effects of two months of subcutaneous octreotide injection therapy on interdigestive gall bladder emptying, motilin release, and the MMC.
All patients had typical clinical features of the acromegaly syndrome, high circulating growth hormone concentrations, which were not suppressed below 2 μg/l after an oral glucose load, and IGF-I (insulin like growth factor-I or somatomedin-C) plasma concentrations above the mean + 2 SD for age. Table I shows patient characteristics. Ultrasound examination of the gall bladder, bile ducts, and liver was performed before the study and showed no stones, sludge or other abnormalities. None of the patients had previously had abdominal surgery. None of the patients were pregnant at the time of the study or receiving any treatment that could potentially interfere with gall bladder motility. Body weight was stable during three months before the study.

Ten healthy volunteers, matched for sex and age (male/female: 7/3, age 38.3 (3.4) (mean (SD) years) served as controls for overnight antroduodenal manometry recordings. All patients and healthy volunteers gave written informed consent. The study protocol was approved by the ethical committee of our hospital.

Protocol
Patients and healthy volunteers fasted from 10 am. At 4 pm a manometry catheter was introduced in the antrum and the duodenum, and subjects went home with the catheter and a portable data recorder. At 7 pm subjects had a standard meal (Stew, Iglo, Utrecht, the Netherlands; 1805 kJ: 27 g protein, 29 g carbohydrate, 23 g fat) and 200 ml of water. After this meal, subjects fasted until the next morning. At 9 am patients returned fasted to the hospital and subsequently two consecutive cycles of the MMC were recorded. For healthy volunteers the study ended when they returned at 9 am. In acromegaly patients, gall bladder ultrasound images were obtained at five minute intervals and blood samples at 10 minute intervals, for two complete MMC cycles. The same procedure was repeated in acromegaly patients after two months of three daily subcutaneous injections of 100 μg octreotide (Sandostatin, Sandoz AG, Basel, Switzerland). During the second test (that is, after introduction of the catheter at 4 pm), patients took octreotide injections (100 μg subcutaneously) at 11 pm and at 7 am and 3 pm on the next day when measurements were obtained.

Manometry
Manometric recordings were obtained with a 6 channel solid state pressure sensor catheter (Gaeltec, Dunvegan, Scotland) with pressure sensors at 5, 20, 25, 28, 31, and 34 cm from the tip. After introduction through the nose, the catheter was positioned under fluoroscopic control, with three to four sensors in the antrum (3 cm apart) and two to three sensors in the duodenum. The catheter was connected to a portable data recorder (Medical Measurement Systems, Enschede, the Netherlands). Sample frequency was 4 Hz. The exact times of meals and octreotide injections were shown by pushing event buttons on the data recorder. After overnight recordings had been obtained, data were transferred from the data recorder to the main computer and stored. In acromegaly patients, the catheter was left in situ and connected to a polygraph (Model 7E, Grass Instrument Co, Quincy, MA, USA; paper speed 25 mm/min.) In this way, on line inspection of motility tracings was possible.

Manometric recordings were continuously monitored by one investigator. During phase III like activity, duodenal contractions were never seen in the antral channels.

Analysis of pressure recordings
Manometric recordings were analysed visually. The most proximal duodenal recording site was used to identify phase I, II, and III. Phase I was defined as a period with no contractions, starting just after the end of phase III. Phase I ended and phase II started when contractions occurred at a rate of more than two per 10 minutes but less than two per minute in the antrum and less than 10 per minute in the duodenum and jejunum. Phase III was defined as rhythmic contractile activity, with a frequency of two to three contractions per minute in antrum during two minutes and 10–12 contractions per minute in the duodenum and the jejunum during three minutes.16 17 Phase III had to be propagated over at least three recording sites and had to be followed by phase I or quiescence. To be taken into account, antral phase III had to be propagated to the duodenum.16 In all cases, antral phase III was followed by duodenal and jejunal phase III. All activity fronts that started in the duodenum, were propagated over at least two recording sites. The site of origin of each phase III was noted. Total cycle length was calculated from the end of phase III in proximal duodenum to the end of next phase III. To compare motility patterns of healthy volunteers and acromegaly patients properly, the two additional MMC cycles, measured in acromegaly patients, were not included in the analysis. The length of the postprandial period was defined as the time from meal ingestion to the occurrence of the first phase III.

A quantitative description of phase III was obtained by multiplying the incidence of contractions with the mean amplitude of contractions during phase III.14

Gall bladder volume measurements
When the patient returned to the hospital in the morning, gall bladder volume was measured by real time ultrasonography (SDR 1500, Philips Ultrasound, Santa Ana, CA, USA: 5.0 MHz transducer). Sagittal and transverse scans of the gall bladder at its largest dimensions were obtained. Gall bladder images were made every five minutes during two complete MMC cycles. These images were stored on videotape and processed by a
TABLE II  Parameters of interdigestive antroduodenal motility in healthy subjects (n=10) and acromegaly patients (n=6) before and after two months of octreotide (mean (SEM))

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Healthy subjects</th>
<th>Acromegaly patients before octreotide</th>
<th>Acromegaly patients during octreotide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recording time (h)</td>
<td>16.3 (0.3)</td>
<td>16.4 (0.9)</td>
<td>15.8 (0.9)</td>
</tr>
<tr>
<td>Length of postprandial period (h)</td>
<td>8.0 (0.8)</td>
<td>6.4 (0.8)</td>
<td>3.1 (0.6)*</td>
</tr>
<tr>
<td>No of MMC cycles</td>
<td>3.6 (0.5)</td>
<td>4.3 (0.9)</td>
<td>8.0 (1.3)</td>
</tr>
<tr>
<td>MMC cycle/min</td>
<td>0.74 (0.06)</td>
<td>0.66 (0.06)</td>
<td>0.84 (0.08)</td>
</tr>
<tr>
<td>MMC cycle length (min)</td>
<td>85.7 (7.8)</td>
<td>99.6 (13.3)</td>
<td>76.0 (9.8)*</td>
</tr>
<tr>
<td>Phase I (min)</td>
<td>46.6 (5.7)</td>
<td>61.0 (10.0)</td>
<td>48.8 (3.9)</td>
</tr>
<tr>
<td>Phase II (min)</td>
<td>33.3 (5.4)</td>
<td>31.5 (11.2)</td>
<td>20.0 (7.8)</td>
</tr>
<tr>
<td>Phase III (min)</td>
<td>5.8 (0.5)</td>
<td>7.2 (1.6)</td>
<td>7.2 (0.4)</td>
</tr>
</tbody>
</table>

Antral/duodenal phase III no

| Spontaneous phase III                  | 14/22            | 9/17                                 | 1/47*                                |
| Phase III contraction incidence        | 10.7 (0.3)       | 10.5 (0.4)                           | 9.0 (0.4)                            |
| (contraction/min)                      |                 |                                      |                                      |
| Phase III contraction amplitude (kPa)  | 3.9 (0.2)        | 4.4 (0.2)                            | 4.0 (0.1)                            |
| incidence×amplitude                   |                 |                                      |                                      |
| (contraction/min×kPa)                  | 41.4 (2.5)       | 46.6 (3.4)                           | 40.0 (2.3)                           |
| Ocreotide induced phase III            |                 |                                      |                                      |
| Phase III contraction incidence        | NS               | NS                                   | 10.6 (0.4)                           |
| (contraction/min)                      |                 |                                      |                                      |
| Phase III contraction amplitude (kPa)  | NS               | NS                                   | 4.7 (0.3)*                           |
| (contraction/min×kPa)                  | NS               | NS                                   | 49.9 (4.7)                           |

* = significantly different from healthy subjects and before octreotide treatment (p<0.05).
† = significantly different from spontaneous phases III during octreotide treatment and from healthy subjects (p<0.05).

MS-DOS computer, using a video grabber and processing software (IBAS, Kontron, Munich, Germany). Gall bladder volume was calculated with the sum of cylinders method.18

Plasma hormone analysis

An in dwelling cannula in the antecubital vein was used to take blood samples at 10 minute intervals for two complete MMC cycles. Blood was collected in ice chilled tubes, preloaded with 50 µl aprotinin (Trasylol, Bayer, Leverkusen, Germany) per ml blood. Plasma was stored at −20°C until analysis. Plasma motilin concentrations were measured by a sensitive and specific radioimmunoassay, without knowledge of the motility recordings, as described previously.19 During the second test, every 30 minutes, blood samples were taken for octreotide concentrations. Plasma octreotide concentrations (in pg/ml) were assessed by radioimmunoassay (Sandoz, Basle, Switzerland).

Statistical analysis

Changes of gall bladder volumes and motilin concentrations were examined by repeated measures analysis of variance. When a significant difference was detected, results were further compared for contrasts by Fisher’s LSD test. Parameters of fasting antroduodenal motility were compared between healthy subjects and acromegaly patients with the Mann-Whitney test. Comparisons before and during octreotide treatment of patients with acromegaly were made with Wilcoxon’s test. All values were given as mean (SEM). Statistical significance was defined as a two tailed probability of less than 0·05.20 To avoid interference from intra and inter subject variation of MMC cycle length, each total cycle length was set at 100% and divided into 10 segments of 10%.

Results

Motility recordings

Table II gives the results of the ambulatory antroduodenal recordings in acromegaly patients and healthy controls. No significant differences for interdigestive motility parameters were found between healthy volunteers and untreated acromegaly patients. The length of the MMC cycle decreased from 99·6 (13·3) min to 76·0 (9·8) min (p<0·05) during octreotide treatment. Although the length of phase I and II decreased during octreotide treatment with 20% and 37% respectively, differences did not reach statistical significance. The number of MMC cycles increased from 4·3 (0·9) to 8·0 (1·3) during octreotide treatment (p<0·05; Fig 1).

In the untreated acromegaly patients, phase III originated in nine of 26 MMC cycles in the antrum, whereas only one of 48 of phase III like activity originated in the antrum during octreotide treatment (p<0·05). Subcutaneous injection of 100 µg octreotide invariably induced a duodenal phase III like activity after 5·9 (0·4) min.

The amplitude of duodenal phase III like activity directly after octreotide injection (4·7 (0·3) kPa) was significantly higher compared with the spontaneous phases III during octreotide treatment (4·0 (0·1) kPa) or with phases III in healthy volunteers (3·9 (0·2) kPa; p<0·05). All other phase III like activities during octreotide treatment were comparable with spontaneous phases III in healthy subjects and untreated acromegaly patients (Table II).

In acromegaly patients, octreotide treatment considerably reduced the duration of the postprandial period after the evening meal from 6·4 (0·8) h to 3·1 (0·6) h (p<0·05).

Gall bladder volumes

Gall bladder volume was monitored during 12 MMC cycles in the untreated state. Four MMC cycles had phase III starting in the antrum and eight at the level of the duodenum. Before octreotide treatment, a significant decrease of gall bladder volume during the cycle was only seen in MMC cycles with antral phase III and not in MMC cycles with phase III starting at the level of the duodenum (Fig 2). Minimum gall bladder volume was reached between the 81st and 90th percentile of the MMC cycle, just before phase III. Maximum decrease of gall bladder volume in MMC cycles with antral phase III (39·9 (4·0%) was significantly larger compared with MMC cycles with duodenal phase III (17·4 (5·8%); p<0·05).

During octreotide treatment, gall bladder volume was monitored during 11 MMC cycles in which all phases III started at the level of the duodenum. No significant gall bladder volume fluctuations were seen during the MMC cycle. Maximum decrease of gall bladder volume was 20·3 (3·7%) during octreotide treatment, which was comparable with maximum gall bladder emptying in MMC cycles with duodenal phase III in the untreated state.
Mean fasting gall bladder volume before octreotide treatment was 40.9 (9.1) ml and increased to 68.0 (14.8) ml (p<0.05) after two months of octreotide treatment.

**Plasma motilin concentration**

In the untreated state, only MMC cycles with antral phase III showed a significant increase of motilin concentrations at the end of phase II, just before phase III (Fig 3). In MMC cycles with duodenal phase III, no significant change of motilin concentrations was seen. During octreotide treatment, motilin concentrations were suppressed to 49.0% of the lowest concentration in the untreated state (p<0.05) and showed no significant fluctuation during the MMC cycle (Fig 3). In one patient, plasma motilin concentrations were below the detection limit of the assay (24 pg/ml) during two MMC cycles.

**Discussion**

Three daily subcutaneous octreotide injections are commonly used for the treatment of acromegaly. However, a high incidence of gall stones (between 13–50%) after one year of treatment was reported. Recently, several mechanisms have been elucidated, which may participate in the pathogenesis of gall stones in these patients.

Firstly, octreotide reduces the secretion of the bicarbonate rich fraction of the bile, increases biliary cholesterol saturation, and increases the fraction of the hydrophobic bile acid deoxycholate. Deoxycholate may participate in the pathogenesis of cholesterol gall stones.
Octreotide, MMC, and gall bladder motility

Secondly, acute octreotide administration reduces postprandial gall bladder emptying probably through suppression of cholecystokinin release. In addition, somatostatin has been shown to suppress acetylcholine release. In several studies increased postprandial residual and fasting gall bladder volumes were seen. Impaired gall bladder emptying may provide time for cholesterol crystal precipitation from supersaturated bile and subsequent gall stone formation. Microscopic examination of duodenal bile from acromegaly patients treated with octreotide showed cholesterol crystals in 64% of patients.

This study showed for the first time that during two months octreotide treatment interdigestive gall bladder emptying is also severely impaired. Figure 2 showed only small gall bladder volume fluctuations during octreotide treatment, which were not statistically significant, although a type II error cannot be excluded. Impaired interdigestive gall bladder emptying might explain increased fasting gall bladder volume during octreotide treatment. In addition, octreotide increases basal pressure in the sphincter of Oddi, which may further contribute to increased fasting gall bladder volume. In healthy humans, gall bladder bile concentration is maximal during the night with transient biliary cholesterol supersaturation. Reduced bile secretion, as occurs during octreotide treatment, has also been shown to be associated with increased bile lithogenicity. Periodic interdigestive gall bladder emptying with subsequent influx of fresh, dilute hepatic bile, however, may prevent precipitation of cholesterol crystals. Interdigestive gall bladder bile stasis in patients receiving longterm octreotide treatment might lead to progressive concentration of gall bladder bile, which promotes precipitation of cholesterol crystals. This might contribute to the high incidence of cholesterol gall stones.

Effects of octreotide on the MMC of the gastrointestinal tract may be relevant for the effects on interdigestive gall bladder motility. The gall bladder empties periodically in the fasting state, in coordination with the MMC. It was recently shown that interdigestive gall bladder emptying is particularly associated with the subsequent occurrence of antral phase III and a plasma motilin peak. In this study similar findings were made. In untreated acromegaly patients, antral phase III was preceded by significant plasma motilin peaks and gall bladder emptying, which was not the case for phase III starting in the duodenum. After two months of octreotide treatment antral phase III was virtually abolished, no significant gall bladder volume or plasma motilin fluctuation were found, and fasting gall bladder volume was increased. After short term infusion of somatostatin-14 in humans, a significant gall bladder volume reduction was still seen just before phase III like activity. This conflicting result may be explained by pharmacokinetic differences between somatostatin-14 and octreotide and by the length of the treatment period.

As Table II shows, two months of treatment with octreotide significantly increased the number of MMC cycles and decreased MMC cycle length. These findings are in agreement with previous reports on the effects of somatostatin and octreotide in short term experiments. In contrast with previous studies, in which a much more pronounced reduction of phase II was seen in our study octreotide treatment did not significantly decrease the length of phase II. These studies, however, were short lasting experiments carried out in dogs or with somatostatin, while we studied the effects of two months of octreotide treatment in humans for about 16 hours. Therefore different experimental set up, drug or species might explain differences although a type II error cannot be excluded in this study. Moreover, adaptation to effects of octreotide may have occurred during two months of octreotide treatment. Several mechanisms can be proposed by which octreotide may interfere with normal antroudenal fasting motility. Firstly, octreotide may have a direct, local effect on the small intestine. Intraarterial
somatostatin infusion of intestinal segments in dogs suggested that somatostatin induces phase III like activity through a local mechanism.31

Secondly, octreotide may act through suppression of motilin release. Antral phase III can only be induced by motilin or motilin agonists like cromakalim.32 Decreased motilin concentrations during octreotide treatment, as found in our study have also been reported previously.13 14 This might explain the virtual absence of antral phase III in this study.

Thirdly, octreotide may act through the suppression of interdigestive cyclic bile flow. It has been shown that periodic delivery of bile to the small intestine is associated with cyclic motilin release.10 33 34 As interdigestive gall bladder emptying during octreotide treatment is suppressed, no motilin fluctuations might be expected. This suggests that in the small bowel other, only partially motilin dependent or even motilin independent mechanisms, similar to direct octreotide effects as mentioned above, might be responsible for induction of duodenal phase III like activity.

From this study, however, no conclusion can be drawn on the exact mechanism by which octreotide affects the MMC.

In conclusion, this study shows for the first time that two months of subcutaneous octreotide injections suppress interdigestive gall bladder emptying, increase fasting gall bladder volume, suppress motilin concentrations, reduce the occurrence of antral phase III, and increase the incidence of duodenal phase III like activity. These factors may contribute to the increased incidence of gall stones in patients receiving longterm octreotide therapy.

The authors thank Dr M Terlof for calculation of gall bladder volumes and Mrs Harriet for ultrasonographic assistance, Dr J van Bree, Sandoz Switzerland, for octreotide preparations, and Professor YL Koo, Peking University Medical College Hospital, China, for technical assistance. This study was supported by the Netherlands Foundation for Medical Research (NWO-MW) grants 900-212-106 and by the Royal Netherlands Academy of Arts and Sciences.

Part of this work has been presented as poster at the 2nd United European Gastroenterology Week in Barcelona 1993.


